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Background: Autism spectrum disorder (ASD) is genetically and phenotypically
heterogeneous. Former genetic studies suggested that both common and rare genetic
variants play a role in the etiology. In this study, we aimed to analyze rare variants
detected by next generation sequencing (NGS) in an autism cohort from Hungary.
Methods: We investigated the yield of NGS panel sequencing of an unselected ASD
cohort (N = 174 ) for the detection of ASD associated syndromes. Besides, we analyzed
rare variants in a common disease-rare variant framework and performed rare variant
burden analysis and gene enrichment analysis in phenotype based clusters.
Results: We have diagnosed 13 molecularly proven syndromic autism cases. Strongest
indicators of syndromic autism were intellectual disability, epilepsy or other neurological
plus symptoms. Rare variant analysis on a cohort level confirmed the association of five
genes with autism (AUTS2, NHS, NSD1, SLC9A9, and VPS13). We found no correlation
between rare variant burden and number of minor malformation or autism severity. We
identified four phenotypic clusters, but no specific gene was enriched in a given cluster.
Conclusion: Our study indicates that NGS panel gene sequencing can be useful, where
the clinical picture suggests a clinically defined syndromic autism. In this group, targeted
panel sequencing may provide reasonable diagnostic yield. Unselected NGS panel
screening in the clinic remains controversial, because of uncertain utility, and difficulties
of the variant interpretation. However, the detected rare variants may still significantly
influence autism risk and subphenotypes in a polygenic model, but to detect the effects
of these variants larger cohorts are needed.
Keywords: autism spectrum disorder, rare variant, next generation sequencing, panel sequencing, rare variant
burden, cluster analysis, syndromic autism
Abbreviations: ACMG, American College of Medical Genetics; ADHD, attention deficit hyperactivity disorder; ADI-R,
Autism Diagnostic Interview – Revised; ADOS, Autism Diagnostic Observation Schedule; ASD, autism spectrum disorder;
BPD, bipolar disorder; CHARGE, coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and
ear abnormalities; ExAC, Exome Aggregation Consortium; FXS, Fragile-X syndrome; GWAS, genome wide association study;
HGMD, Human Gene Mutation Database; ID, intellectual disability; INDEL, insertion/deletion; MAF, minor allele frequency;
MPA, minor physical anomalies; NGS, next generation sequencing; OCD, obsessive compulsive disorder; PCA, principal
component analysis; VUS, variant with uncertain significance; WES, whole exome sequencing.
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INTRODUCTION
Autism spectrum disorder (ASD) is a neurodevelopmental
disorder, characterized by the core symptoms of impaired
social communication, restricted interests and stereotyped,
repetitive behavior (Bourgeron, 2015). ASD has an estimated
heritability of 64–91% (Woodbury-Smith and Scherer,
2018), suggesting a strong genetic effect, but the genetic
background is highly heterogeneous (Vorstman et al., 2017).
Common risk variants and rare variants both play a role
(Bourgeron, 2015), and mutation types range from single
nucleotide variants to large chromosomal aberrations, as
well as variations in regulatory DNA elements (Turner
et al., 2016). The number of genes implicated in ASD
pathogenesis is >1,000 according to the SFARI database1,
which converge on different cellular pathways (Krishnan et al.,
2016). A shared genetic environment is possible with other
psychiatric disorders as well, especially with schizophrenia
(Brainstorm Consortium et al., 2018).
The clinical expression of ASD is nevertheless varied, despite
the common umbrella term (Chaste et al., 2015). This high
phenotypic variability, however, is mirrored poorly in the
everyday clinical diagnostics of ASD. Indeed, DSM-5 now
contains a single autism spectrum (Lord et al., 2018). This
might be beneficial in the clinic but doesn’t serve the analysis of
the genetic-phenotypic background. Earlier attempts to identify
ASD subtypes or endophenotypes based on clinical features
have met with limited success, and there were attempts to
define subtypes based on genetics, which led for example to
the identification of ASD with CHD8 mutation subtype (Bernier
et al., 2014). According to the classical definition, the syndromic
ASD is a “disorder with a clinically defined pattern of somatic
abnormalities and a neurobehavioral phenotype that may include
ASD,” however, this is only present in 4–5% of cases (Fernandez
and Scherer, 2017). Instead, if we move to a molecularly defined
approach, in 25% of the cases there is a detectable strong genetic
change, which may be even higher if multiple MPA are present
(Fernandez and Scherer, 2017).
MATERIALS AND METHODS
In this study, we aimed to comprehensively analyze rare single
nucleotides, and small INDEL variants in candidate ASD genes
in a Hungarian ASD cohort, with NGS. Specifically, we tried
to answer four questions in two hypothesis frameworks. On
a case-by-case level: (1) How many patients can be detected
with a probably strong acting variant (syndromic cases or
Monogenic disorder) by targeted NGS gene sequencing? On
a cohort level: (2) Is the detected number of variants in the
tested genes significant? Does this confirm the pathogenicity
status of the given genes? (3) Does rare variant burden associate
with autism severity? (4) Do rare variants associate with any
autism subphenotype?
1https://gene.sfari.org/
Patients
Autism spectrum disorder patients were recruited from the
Vadaskert Child and Adolescent Psychiatry Hospital and
Outpatient Clinic. Detailed clinical examinations consisting of
a general medical examination and neurological assessment
(NÁV, PB) were performed. A diagnosis of ASD was made
by a qualified psychologist (CSP) using the ADI-R (Autism
Diagnostic Interview-Revised) and ADOS (Autism Diagnostic
Observation Schedule). Patients were screened for MPA, which
were selected based on the Méhes Scale (Méhes, 1986). Family
history and detailed environmental/societal data were collected
from the parent (or parents) of each patient. Any disorders
present in the parents, as well as environmental factors, were
registered. The diagnosis of ASD was based on the standardized
ADI-R in Hungarian, which was published by the Autism
Foundation (Kapocs Publisher), according to the following
scores: A≥ 10 (social interaction), B≥ 7 (communication), C≥ 3
(repetitive stereotype manner), D ≥ 1 (abnormal development
under 36 months).
Genetic Analysis
DNA was isolated from peripheral blood samples from all
participants using the QIAamp DNA blood kit (Qiagen,
Hilden, Germany) according to the manufacturer’s instructions.
We performed Fragile X-screening at every patient using
the Amplidex FMR1 PCR kit (Asuragen, Inc., Austin, TX,
United States). Since Fragile-X-syndrome is a well-known cause
of syndromic autism, and a unique molecular pathomechanism
is probable, patients having FMR1 gene alteration were excluded
from all subsequent genetic analysis and phenotypic cluster
analysis. The 101 ASD-associated genes (Betancur, 2011)
were investigated with NGS, which was performed on a
MiSeq (Illumina, San Diego, CA, United States) using the
TruSight Autism Rapid Capture Kit (Illumina, San Diego, CA,
United States) and the SureSelect QXT Kit (Agilent Technologies,
Santa Clara, CA, United States) according to the manufacturer’s
instructions. In the autism panel, 24 samples were multiplexed
in a single run using the MiSeq reagent kit v2 and 300 cycles
(Illumina, San Diego, CA, United States). The mean read depth
was 135× in the gene panel, 20× coverage was achieved in
a minimum of 90% of target regions. Pathogenic and likely
pathogenic mutations from NGS data were validated by Sanger
sequencing. Parents were Sanger sequenced for specific variants
in selected cases, where syndromic ASD was suspected based
on the sequencing results of the index case, and the parent was
available for genetic analysis.
Bioinformatic and Statistical Analysis
Raw sequences were filtered with Picard tools (version-
2.1.0)2 and quality filtered reads were aligned to the hg19
reference genome with BWA-mem (Li and Durbin, 2009)
using default parameters. Variant calling was performed using
GATK HaplotypeCaller (version 3.3-0) (McKenna et al., 2010)
and VCF files were annotated with SnpEff (version 4.1)
(Cingolani et al., 2012). We analyzed only those variants that
2http://broadinstitute.github.io/picard/
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were found in the canonical transcripts of the gene. Variant
quality was assessed by GATK, and only variants, which were
flagged as PASS (RD>10, Mapping quality>40, quality by depth
>2) were analyzed.
To filter potentially causal single-gene Mendelian variations
on a case-by-case level, we used the VariantAnalyzer software
developed at the Budapest University of Technology and
Economics. This software application annotates SNPs and short
INDELs with several types of annotations, such as their predicted
function on genes using SnpEff, observed allele frequencies in
several genomic projects including the 1000 Genomes Project
and the ExAC, conservation scores based on PhyloP, PhastCons,
GERP, predicted function of non-synonymous SNPs using
dbNSFP, and disease associations with HGMD and ClinVar. By
creating filter cascades based on these annotations and other
information (e.g., genotypes and variant quality annotations),
the software can easily be used to filter the variants through a
user-friendly graphical interface. First, we filtered for variants
known to be disease-causing, using the HGMD (Cooper et al.,
1998), and ClinVar database (Landrum et al., 2014). Second, we
filtered for rare variants based on the MAF and frequency of
the mutation in our NGS data repository of 200 WES. Since
large-scale genomic data of the Hungarian population is not
available, a mutation with a low MAF may also be population-
specific. We labeled a variant as rare if it was present maximum
in one homozygous or two heterozygous samples within our
ASD cohort of 174 patients (equal to a MAF-cutoff of ∼5h),
and the MAF in Europeans from the 1000 Genomes and ExAC
databases, as well as in our in-house exome database was less
than 5%. It is important to note that a limitation of this
method is that it may exclude identification of founder mutations
and disease-associated polymorphisms. Finally, mutations were
prioritized based on their predicted effects. Exonic frameshifts,
stop mutations and canonical splice site variants were considered
damaging, whereas the effects of missense mutations were
predicted using multiple prediction tools: SIFT (Sim et al., 2012),
Polyphen2 (Adzhubei et al., 2010), CADD (Kircher et al., 2014),
Radial SVM (Dong et al., 2015). The variants were assessed as
recommended by the ACMG guideline 2015 (Richards et al.,
2015). When siblings were analyzed for Mendelian disease-
causing variants, both of them had to be carrier of the variant
in question to be considered.
For the analysis of rare variants in a multifactorial hypothesis
framework on a cohort level, the following methods were used.
(1) We tested, whether the total number of detected rare
missense or loss of function (stop, canonical splice site, and
frameshift) variants in a given gene is greater than expected, with
the method described by Rao and Nelson (2018). We filtered
rare variants, with a MAF cut-off of 5% in the 1000 Genome
European dataset, and in our internal exome database of 200
patients. P-value was calculated with the associated software:
SORVA3. (2) For the calculation of rare variant burden, genes
were normalized according to genic intolerance to mutation
(Petrovski et al., 2013). Specifically, we used the inverse RVIS
percentile [1–(RVIS percentile÷100)] accessed from http://genic-
3https://sorva.genome.ucla.edu/
TABLE 1 | Clinical-demographic features of the cohort.
Sex M/F = 129/45 = 2.86/1
Median age (IQR) 6 (7)/5 (7)
Average ADI
Reciprocal social interaction 23 ± 5,2
Communication (verbal/non-verbal) 13,95 ± 4,2/18,48 ± 2,5
Repetitive behavior 6,66 ± 2,1
ADOS 21,2 ± 5,7
Comorbid diagnosis
ADHD (%) 84/174 (48,27%)
Epilepsy (%) 20/174 (11,49%)
Intellectual disability (%) 70/174 (40,22%)
Ethnicity
Reported Hungarians 170
Reported Romani 2
Other 2
Maternal age at delivery (95% CI) 30,7 ± 1,05
Paternal age at delivery (95% CI) 33,4 ± 1,29
Parent’s education level
College or higher at both parents 34%
College or higher at one parents 27%
High school or lower at both parents 39%
The table describes the characteristics of the cohort. Ethnicity is self-reported. M/F
is male to female ratio.
intolerance.org/, to give a weight to every gene than summed the
number of variants in a given patient [6(variants × weighted-
gene-score)]. For example, if a given gene was in the 2%
percentile with RVIS, that means, that the gene got a weight
of 0,98. When performing variant burden analysis we allowed
to analyze siblings separately, because different rare variants
might contribute to their phenotype, according to our hypothesis.
Linear regression was used then to test for correlation between
rare variant burden and autism severity, and rare variant burden
vs. minor malformation burden. Autism severity was assessed
by the total ADOS score, in patients, at whom ADOS was
available (N = 47), and also by calibrated severity score using
the method described by Gotham et al. (2009). For comparison
of rare variant burden in males versus females, and the number
of minor malformations in syndromic versus non-syndromic
cases two-tailed T-test was used. (3) For the analysis of rare
variant association with potential autism subphenotypes first, we
assessed, whether such subphenotypes can be created based solely
on the clinical data. We have used our clinical questionnaire
containing 149 questions about family history, concomitant
diseases, drugs, physical examination (neurologic and screening
of minor malformations), and psychological status for cluster
analysis. For the phenotypic cluster analysis, given our sample
size and the low expected number of clusters, we utilized
two kernel-based methods, namely kernel PCA and spectral
clustering. Kernel methods have the additional benefit of being
non-linear, i.e., able to identify non-linear combinations of
clinical variables as relevant features. This requires the definition
of a kernel matrix, which can be thought of as a pairwise
similarity matrix over the samples, for which we used the
mutual information as similarity measure in conjunction with
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FIGURE 1 | Total number of minor malformations, and the percentage of different minor malformations in the cohort. The Figure represents the total number of minor
malformations/given individuals as a histogram (A), and the prevalence of different minor malformations, as a percentage of the total cohort (N = 174) (B).
the binarized clinical variables. In accordance with earlier studies,
we set the number of clusters in spectral clustering to four.
We also investigated the variables characterizing each cluster
via computing the relative frequency of the presence of each
feature. We performed the kernel PCA with 3 dimensions
to visualize the transformed samples and cluster assignments.
A natural question to ask is whether we can find a correlation
between the subphenotypes and the genetic background, hinting
at causal roles of genes in a given phenotype. In our case, the
former is given by the clusters resulting from the questionnaire
and the latter is given by the detected rare variants aggregated
on candidate genes. To assess the correlation between the
subphenotypes and genetics, we investigated whether detected
rare variants of a candidate gene occur more frequently in
either of the resulting clusters using ANOVA and pairwise
T-tests, in conjunction with Bonferroni correction for multiple
hypothesis testing.
RESULTS
Phenotypic Description of the Cohort
One hundred and seventy-four individual with ASD [45 females
and 129 males, median age = 6 years, interquartile range
(IQR) = 7] were included in our study, including 5 sib-
pairs. Clinical-demographic features of the cohort are presented
in Table 1.
Minor somatic abnormalities were frequent, at least one minor
abnormality was present in 84% of the cohort from the Méhes
scale. Histogram of the number of minor malformation per
individual and the frequency of different minor malformations
are shown in Figure 1. In general, molecularly diagnosed
syndromic patients (13 cases, see next section) had on average
no more minor malformations compared to non-syndromic
cases (average number of minor malformations were 4.9/person
in syndromic, and 5.03/person in non-syndromic cases, T-test
p = 0.91). Strongest indicators of molecularly provable syndromic
autism were ID, epilepsy or other neurological sign (such as
ataxia), or a specific constellation of minor abnormalities as in
the case of Fragile-X (FXS) and CHARGE syndrome.
Positive family history (as reported by the parents) for
psychiatric or neurological disorders were also common
(Figure 2). ASD occurred at a first degree relative at 14
patients (8%), and at a second degree relative at 17 patients
(9,7%). Besides psychiatric disorders, epilepsy (2,8% at first
degree relatives, and 4,0% at second degree relatives), muscle
hypotony (7 and 0%), speech development delay (10 and 6%),
ID (5 and 11%), dysmorphic features (12 and 4%, respectively)
were also common.
Syndromic Forms of ASD
We have diagnosed 13 syndromic autism cases based on
genetic findings (Table 2). Four patients were diagnosed
with Fragile X syndrome, detected by screening, but these
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FIGURE 2 | Family history of the probands. The figure is showing the probands with positive family history. Every row represents a single patient. Light red indicates,
when a second-degree relative was affected with a given condition, and dark red indicates, when a first-degree relative was affected. Hierarchical clustering was
applied on the heat map for better visualization. ADHD, attention deficit hyperactivity disorder; ASD, autism spectrum disorder; BPD, bipolar disorder; ID, intellectual
disability; OCD, obsessive-compulsive disorder.
patients also had phenotypes consistent with FXS besides the
definite autism. However, one of them is a girl (P1). In
this case, the family history (2 healthy brothers), did not
suggest an X-linked inheritance. Overall eight mutations were
considered as pathogenic according to ACMG classification,
with close phenotype match (four patients with FXS, one
patient with Dravet syndrome, one patient with CHARGE
syndrome, one patient with Duchenne muscular dystrophy,
one patient with atypical Rett syndrome), and clear additional
features (ID, epilepsy, muscular dystrophy, and multiple minor
malformations) suggesting syndromic autism. The muscular
dystrophy at the Duchenne patient (P7) was already known
before the NGS study.
One likely pathogenic mutation occurred in the PTPN11
gene. The phenotype in this case (P9) was not typical
for Noonan syndrome, however, the detected variant was
reported earlier as pathogenic in ClinVar (RCV000037618.3)
by a single submitter, the variant is rare (absent from
1000G and ExAc database, single occurrence in the cohort,
absent from 200 Hungarian WES), predicted consequently as
damaging by multiple prediction algorithms (SIFT, Polyphen,
CADD, and MetaSVM), the gene is associated with dominant
inheritance, and the variant is located in an evolutionarily
conserved region (GERP score 5.13). Segregation analysis
was not possible in this family. We detected two likely
pathogenic variants in the RELN gene with different phenotypes.
A heterozygous RELN variant (NM_005045: p.P672L) was
present in a patient (P10) with epilepsy and multiple minor
anomalies. This variant is also reported as pathogenic in
the ClinVar database (RCV000193679.1). Segregation analysis
proved that the variant is inherited from the father, who
had no epilepsy, however, incomplete penetrance is possible
according to the literature (OMIM:616436). At the case of
P11, a de novo variant occurred in the RELN gene. The
lissencephaly phenotype is associated with autosomal recessive
inheritance according to the databases, but we classified this
variant as likely pathogenic instead of a VUS, because of its
proven de novo status. To rule out other possible genetic
causes, an additional commercial lissencephaly panel testing was
also performed (at Centogene, Rostock, Germany) which gave
the same result.
Two variants were classified as VUS. At the case of P12,
the detected SPAST variant is reported as likely pathogenic in
the ClinVar (RCV000199081.1), however, neither the patient nor
the mother, who is also a carrier of the variant, have spasticity.
In the case of P13, an unusual molecular event occurred. Two
single nucleotide variants affected a single codon in the AUTS2
(KIAA0442) gene (as proved by visualizing BAM files, and
Sanger sequencing), resulting in p.E814M amino acid change.
The phenotype is consistent with the literature (OMIM:615834),
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however, segregation analysis was not possible in the family.
This patient died later as a consequence of a severe epileptic
seizure. In total four variants was proved as de novo, and
five variant was inherited. At four cases segregation analysis
could not be performed in order to determine, whether the
variant was de novo or inherited. The graphical representation
of detected mutations in syndromic cases are presented4
in Figure 3.
Cohort Level Number of Rare Variants in
the Candidate Gene Panels
The total number of different rare variants (as defined in the
section “Materials and Methods”), was 370. Among the 101
candidate gene, 80 genes contained rare variants, and 44 genes
contained a rare predicted pathogenic variant (CADD score≥ 20
OR SVM = damaging). These 44 genes are represented in
Figure 4. Loss of function mutations occurred in 8 genes:
AUTS2, CHD7, DHCR7, DMD, GNA14, MECP2, SHANK2, and
SHANK3 gene. Among these genes, AUTS2, CHD7, SHANK2,
and SHANK3 can be considered highly intolerant to functional
variants (RVIS < 5 percentile), which suggest a pathogenic role
for these genes. A table describing the number of different types
of variants (missense, nonsense, frameshift INDEL, and non-
frameshift INDEL) in all the investigated genes is provided as
Supplementary Table S1.
We have used the software SORVA, with the method described
by Rao and Nelson (2018) to assess whether the total number
of rare missense and loss of function variants is greater than
expected in the tested genes. Significantly greater than expected
number of rare variants were detected in 5 of the 101 tested
autism-linked genes: AUTS2, NHS, NSD1, SLC9A9, and VPS13B
(Table 3). Rare variant burden did not differ between females
and males (mean = 3.49 for males and 3.31 for females;
p = 0,57). There was 67 individual (38.5%) in the cohort who
did not carry any rare, predicted damaging variant in the
candidate genes.
Correlation of Rare Variant Burden With
Autism Severity
Autism severity was calculated by two methods: total raw
ADOS score (available from 47 patients), and calculating
calibrated severity score from ADOS raw total as described
in the Section “Materials and Methods.” For the purpose of
correlation analysis, we found that the calibrated severity
score was not suitable, because most of the patients, who had
ADOS fall into the most severe categories (8–10 score).
ADOS raw total scores were better distributed among
individuals (Figure 5), however, there was no correlation
between ADOS raw total scores and rare variant burden
by linear regression analysis (R2 = 0,0047; p = 0,648)
(Figure 5). There was no correlation between rare variant
burden and the number of minor malformations neither
(R2 = 0,003; p = 0,51).
4http://mutationmapper.bioch.ox.ac.uk/
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FIGURE 3 | Variant position in syndromic cases. The graphical representation of the variants detected in syndromic ASD cases are presented. This was created with
the mutation mapper software.
Cluster Analysis and Gene Enrichment in
the Phenotypic Clusters
The identified clusters and the most frequent 10 characterizing
variables are shown in Figure 6. It can be seen that total 22 feature
is involved in the 10 most common features of the clusters, thus
significant overlap exists between the clusters. However, there are
features, that particularly characterize certain clusters. Cluster_3
might be characterized by severe social disturbances, with
prominent speech disturbance and social isolation. Cluster_4 is
probably fitting into the ASD with comorbid ADHD category.
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FIGURE 4 | Genes, which contained rare, predicted pathogenic variants. Gene network representation of the genes, which harbored rare, predicted variants was
created with STRING (https://string-db.org/). Edges represent interactions between the genes. It can be seen, that the interaction network contains a set of genes
strongly connected (namely involved in nervous system development pathway GO:0007399; p = 3.22e-15), however, this is only suitable for demonstration
purposes since the panel selection is a bias in the pathway analysis.
Cluster_2 is characterized by ID plus frequent obsessive-
compulsive (OCD) features with uncompensated behavior.
Cluster_1 is the hardest to interpret, but one outstanding feature
is the presence of BPD in the family and more than one minor
physical anomaly. However, gene enrichment analysis did not
show a significant overrepresentation of single genes in certain
clusters. Syndromic cases were not enriched into a single cluster.
DISCUSSION
According to the literature, the overall heritability of ASD is
estimated to be around 64–91% (Tick et al., 2016), suggesting
a strong genetic factor in the background, but the underlying
genetics seems to be very complex. The current models of autism
genetics implicate a miscellaneous genetic environment, where
common and rare variants act additively to create a risk for
ASD (Weiner et al., 2017). According to Bourgeron’s hypothesis,
common low-risk alleles set the background risk for ASD, and
buffer the effects of rare deleterious variants (Bourgeron, 2015).
While it is estimated that common variants account for
40–60% of the overall liability of ASD (Klei et al., 2012),
most genome-wide association (GWAS) studies were until now
underpowered, and very few loci have been identified with
genome-wide significance (Ramaswami and Geschwind, 2018).
In contrast, hundreds of genes were described with rare variants,
which significantly increase the risk of ASD, and it is estimated
that they account for approximately 10–30% of autism cases
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TABLE 3 | Genes with an unexpectedly high number of rare variants.
Genes Length_of_
protein (AA)
Count_variants
(variant/indiv+ shared_
variant/sib_pairs)
SORVA_p_value
AUTS2 1259 30/164 + 0/5 8.50E-06
NHS 1651 17/164 + 0/5 0.000149848233
NSD1 2696 53/164 + 0/5 8.40E-12
SLC9A9 645 17/164 + 1/5 0.026
VPS13B 4022 55/164 + 0/5 5.50E-05
The table shows the genes, in which a significantly greater number than expected
rare variant occurred. P-value was calculated with the SORVA software (MAF cut-
off 5%). We summed the variants (heterozygous or homozygous) in the given gene
in unrelated individuals (variant/indiv). In sib pairs, those variants were counted,
which were shared (shared_variant/sib pairs).
(Fernandez and Scherer, 2017). Examples of evidence are
an increased ASD risk with single rare variants of NLGN1
(Nakanishi et al., 2017), VPS13B (Ionita-Laza et al., 2014),
GABRB3 (Delahanty et al., 2011), and PTCHD1 (Torrico et al.,
2015). However, the contribution of these variants on a cohort
level might be small. For example, a large WES study identified
the strong risk factor gene CHD8, but pathogenic variants were
only present in 15 out of 3,730 ASD cases (0.4%) (Bernier et al.,
2014). For this reason, WES studies need very large sample
sizes to reach a genome-wide significance (Liu et al., 2013).
A possible solution to increase detection rate in WES studies is
focusing on genes within shared haplotypes among individuals
with ASD (Matsunami et al., 2014) or within regions that have
been implicated by common variant GWAS analysis in large
case-control cohorts, and collapsing individually rare variants on
genes (burden-analysis) (Griswold et al., 2015).
In this study we utilized the method and software, developed
by Rao and Nelson (2018), to test the gene level burden on a
cohort level. This approach allowed us to use a general control
group from earlier exome sequencing projects. In order to
avoid population-specific variants, we excluded variants over 5%
MAF in our in-house exome database. Significantly greater than
expected number of rare variants were detected in five genes
(AUTS2, NHS, NSD1, SLC9A9, and VPS13B), which confirm their
role as a strong risk modifier gene. Due to our low cohort size,
however, we could not confirm the roles of other candidates, or
well-known ASD risk genes. We also tested, whether rare variant
burden is correlated with autism severity, or the number of minor
somatic abnormalities, but found no correlation. However, this
might also be due to our low sample size.
The change of the view on the AUTS2 gene is highlighting
an important issue with rare variant interpretations in a
complex disorder, like ASD. As knowledge was gathered, the
view of AUTS2 gene changed from an “autism susceptibility
candidate gene” to a cause of a syndromic form of ASD (“AUTS2
syndrome”), with frequently associated ID, microcephaly
and craniofacial abnormalities (Hori and Hoshino, 2017).
We speculate, that this might also happen with other genes
too. In our study, we identified loss of function mutations
in the GNA14, SHANK2, and SHANK3 genes, which are
yet not linked to a characterized syndrome, but they are
evolutionary intolerant to functional mutations. This makes
genetic counseling very difficult in these cases. Further
problems arise by the fact that ACMG interpretation is
not suitable for the assessment of these genes (Richards
et al., 2015), so there is no standardized framework for
pathogenicity interpretation.
Many of the rare variants, detected in ASD studies, are de
novo, according to the literature (O’Roak et al., 2011), and might
act together with common polygenic risk variants, in a way,
where rare variants modulate the ASD phenotype. Weiner et al.
(2017) study showed that ASD cases with a strong acting de
novo variant also carry a greater than expected polygenic risk,
independently from the presence of the de novo variant. However,
the presence of a de novo variant associated with an increased risk
of co-occurring adverse neurodevelopmental outcomes (delayed
walking, seizure, and ID). In our study, four of the 13 variants,
linked to a syndromic autism case, were proved to be de novo.
However, we could not perform segregation analyses in the
whole cohort, for non-syndromic cases, to check whether the
detected rare variants are de novo or not, therefore cannot draw
further conclusions.
Due to the known challenges of phenotypic heterogeneity
and variability of clinical presentation, identifying phenotypic
subgroups has been a long-standing goal in ASD research
(Prior et al., 1998). Previous studies indicate that objective
approaches, such as dimensionality reduction methods
(Tadevosyan-Leyfer et al., 2003) and cluster analysis (Verté
et al., 2006; Hu and Steinberg, 2009; Hu and Lai, 2013) can
be utilized in establishing homogeneous subgroups based on
clinical features. In particular, linear methods, such as PCA,
k-means and hierarchical clustering have been applied. Studies
showed that the resulting clusters indeed characterized by certain
symptoms (such as severe language deficits) and correlate with
gene expression profiles (Hu and Steinberg, 2009). In this study,
we identified four reasonable phenotypic clusters by spectral
method, but could not find genes, which are enriched particularly
in a given cluster. Syndromic cases were also not enriched into
a single cluster.
The main purpose of phenotypic cluster analysis would be to
potentially identify homogenous subgroups (endophenotypes),
which may be linked to specific genetic background,
pathogenesis, perhaps therapeutic approach. The phenotypic
subgroups identified in this study show partial overlap with
former studies. One of the strongest characterizing feature,
which seems to be recurring in more studies is the presence of
language impairment. Indeed it is also specified in the DSM-V
(ASD with accompanying language disorder). Further distinctive
features, which are clearly identifiable are association of ID,
attention deficit and hyperactivity, and obsessive-compulsive
features. It worth to mention, that many earlier attempts
to identify ASD subgroups were mainly based on standard
diagnostic questionnaires (Tadevosyan-Leyfer et al., 2003;
Hu and Steinberg, 2009; Kienle et al., 2015; Cholemkery
et al., 2016). The strength of this approach, that it utilizes
existing resources to demonstrate, that subgroups may also
be delineate on a spectrum disorder. However, there is a
question whether this can provide new information. There
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FIGURE 5 | Autism severity scores calculated from ADOS, and the correlation between rare variant burden vs. ADOS scores. Panel (A) shows the scatter plot of
ADOS raw total scores (blue points), and the calibrated severity scores (red points). Calculated scores were distributed only between 7 and 10, thus raw total scores
were used for linear regression analysis (B).
is an opportunity also to use other resources too, such as
electronic health records (Doshi-Velez et al., 2014), or brain
imaging data (Hrdlicka et al., 2005). In our approach we
used parental interview, and data on physical examination.
On one hand we also have seen that language impairment,
attention deficit, hyperactivity, and OCD features are important
distinctive features. On the other hand we identified an
additional cluster, where somatic malformation might be
an outstanding feature. However, this need to be confirmed
in larger samples, and possibly beneficial is a combined
method (i.e., using standardized questionnaires together with
additional data).
Besides the patients with rare genetic variants acting as a
strong risk factor, a small group of ASD is called syndromic,
where a single genetic variation (such as FMR1 repeat expansion,
PTEN, TSC1, or MECP2 mutation) is considered as causal
(Fernandez and Scherer, 2017). It is estimated that approximately
10–25% of individuals with ASD carry a highly penetrant genetic
alteration, which might explain the phenotype (Bourgeron,
2015). In our cohort, we identified 13 syndromic patients
(7,47% in total and 5,17% if we don’t consider Fragile
X patients detected by screening). This is somewhat lower
than the above-mentioned average, however, we only analyzed
single nucleotide variants and small INDELs, which is a
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FIGURE 6 | Result of the phenotypic cluster analysis. The three-dimensional figure (A) shows the result of kernel PCA with the identified phenotypic clusters. The
histogram (B) represents the relative frequency of the 10 most common features in the given clusters.
limitation of this study. In a recent study, microarray, Fragile
X testing and targeted gene panel testing was performed in
100 children with ASD (Kalsner et al., 2018). Copy number
variants believed to contribute to ASD risk were identified
in 12%, but the gene panel did not increase the diagnostic
yield. It has to be mentioned although, that rare variants,
not considered as causing a syndrome, might also significantly
modify the phenotype (such as IQ, head size) (Pizzo et al.,
2018). This again draws the attention to the issue that
the clinical interpretation of these variants may significantly
differ among laboratories. It has to be mentioned also, that
none of the identified syndromic cases was unexpected, in
a sense that all of them had additional signs suggesting
syndromic autism ab ovo.
Potential clinical translation of genetic diagnosis can be
manifold. In the syndromic group it helps to estimate
recurrence risk, the prognosis, potential specific comorbidities,
and therapeutic approaches. Taking these into account, well-
proved syndromic ASD-associated genes need to be investigated
at least in the clinically defined ASD-group. The phenotypic
clustering can potentially help to correctly identify which group
has to be tested. In the group of non-syndromic ASD the
indication for genetic investigation is currently less clear. In
this group the simultaneous effect of the different common
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and rare variants should be estimated, which is currently
dubious. Polygenic risk scores are emerging as a tool to predict
disease risk in multifactorial diseases, but have many potential
bias (De La Vega and Bustamante, 2018; Torkamani et al., 2018).
Even so polygenic risk score show promise, for example earlier
studies showed that ASD polygenic risk score is positively
correlated with general cognitive ability (Clarke et al., 2016),
or with specific fMRI connectivity pattern (Wang et al., 2017).
However, we are far away from everyday clinical utilization.
Certain limitations of the study should be mentioned. The
size of the cohort is perhaps the most important one. As we
looked specifically for rare variants in a relatively small cohort,
the probability of finding variants with very low MAF is low. This
could explain our result, that only five gene had significantly more
rare variant burden than expected by spontaneous mutation
rate, gene size and genic intolerance. This can result in false
negative findings. False positive findings may also arise due to
small sample size, however, this is mitigated by the fact, that
well established ASD-genes were included in the panel. However,
this approach has also disadvantages. The low number of total
variant detected made impossible to analyze ethnicity and cryptic
relatedness from the genetic data. On the other hand selection of
a gene panel always contains a bias, since the number of genes
linked to ASD is around 1000 according to the SFARI database5.
However, many of these do not have an associated Mendelian
disorder. Finally we did not carry out functional experiments in
this study, so cannot distinct clearly between rare non-functional
and rare functional variants. We used protein prediction scores
to assess the probability of functional impact of a variant.
CONCLUSION
In this study, we performed an analysis of rare single
nucleotide and small INDEL variants in a Hungarian ASD
cohort, detected by NGS panel testing, in order to identify
syndromic autism cases and to assess the contribution of
rare variants in formerly established ASD genes on a cohort
level. Our study indicates that NGS panel gene sequencing
can be useful in dedicated cases, where the clinical picture
suggests a clinically defined syndromic autism (i.e., associated
ID, epilepsy, neurological signs, a certain pattern of somatic
malformation, or positive family history). In this group, targeted
panel sequencing may provide reasonable diagnostic yield.
However, the necessity of unselected NGS panel screening in
the clinic remains controversial, because of uncertain clinical
utility, and difficulties of the variant interpretation. The detected
rare variants may still significantly influence autism risk and
subphenotypes in a polygenic model. However, to detect
the effects of these variants large cohorts are needed. As
knowledge will increase about the contribution of these rare
variants on the phenotype, an individual assessment might also
be beneficial in the future for personalized management of
patients with ASD.
5 https://gene.sfari.org/
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